CD274 and neoplasm: For example, in phase 1b KEYNOTE-028 trial, enrolling only PD-L1-positive pretreated patients with MPM (with positivity defined as immunohistochemistry expression in at least 1% of tumor cells) to receive pembrolizumab, promising results in terms of durability and efficacy of response were observed (11).